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Background: Dyslipidemias are one of the major modifiable risk factors for cardiovascular disease. Familial hypercholesterolemia (FH) is 
the most common genetic metabolic disorder; it is estimated that around 14-34 million people worldwide have FH but only 25% of FH 
patients have been diagnosed.  
Aim: The aim of the present study was to explore the prevalence of FH in Attica region, Greece. 
Methods: Attica region was divided into 8 regional units. A predesigned questionnaire was used to collect demographic and clinical 
data. Data analysis was performed by using the Statistical Package for the Social Sciences (SPSS), ver. 20. 
Results: The studied sample consisted of 1578 Greek inhabitants of Attica region. The majority of the sample was women (59.9%). The 
mean age of the studied participants was 47.1 (±14.9) years. According to Simon Broome criteria, the probability of an FH diagnosis as 
unlikely is determined in 98.7% of the studied sample, probable in 0.8% of the participants or definite in 0.5% of the participants, based 
on this data, the prevalence of FH in Attica region, Greece is 1:200. Qualitative factors found to be associated with the onset of the dis-
ease were medication (p-value = 0.001) and hypolipidemic therapy (p-value = 0.001). The quantitative factors found to be associated 
with disease onset were body mass index (p-value = 0.044), and systolic (p-value = 0.001) and diastolic (p-value = 0.007) pressure.  
Conclusions: Based on our data, the prevalence of FH in Attica region, Greece is 1:200. Early identification of contributing factors in FH 
development and proper treatment is vital and reduce the risk of premature and severe atherosclerotic disease. 
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INTRODUCTION 
Cardiovascular diseases (CVD) are the leading cause of death 




The problems that affect the circulatory system derive from 
atherosclerosis. Atherosclerosis is a chronic inflammatory con-
dition in large and middle-sized arteries, where activated im-
mune competent cells are abundant and as a consequence 
plaque rupture may be triggered.
2,3
  
The presence of atherosclerosis is evidenced across various 
geographic regions, cultures and lifestyles.
4 
According to Euro stat, the death rate for cardiovascular dis-
ease was 258 deaths per 100.000 inhabitants in 2016 in both 
high and low-income countries.
5 
CVD mortality rates in Greece have decreased during the last 
15 years, a fact that could be partially attributed to the lower 
prevalence of smoking and the increase in physical activity 
among the Greek population.
6
 According to data from the Hel-
lenic Statistical Authority (ELSTAT), developed by the Institute 
for Economic and Industrial Research (IOBE), which cover the 
period 2000 - 2012, there are significant changes in the causes 
of death in Greece. Vlachadis et al.,
7
 analyzed official national 
data for causes of death in Greece concerning the period 
2004–2012 and they concluded that the decreasing trends in 
CVD mortality, being witnessed in the pre-crisis period, re-
mained unaffected during the years of the crisis (2008–2012).  
Dyslipidemias are one of the major modifiable risk factors for 
cardiovascular disease. Familial hypercholesterolemia (FH - 
Familial Hypercholesterolemia) belongs to the primary 
dyslipidemias in which defective genes disrupt the metabolic 
pathway of lipid and sterol clearance. FH is the most common 
genetic metabolic disorder and one of the few underlying ge-
netic disorders known as dyslipidemia. It is estimated that 
around 14-34 million people worldwide have FH but only 25% 
of FH patients have been diagnosed.
8
  
The disease is mainly due to low density lipoprotein (LDL) re-
ceptor gene mutations, which cause reduced functionality or 
reduced receptor production, resulting in decreased catabolism 
of LDLs and their accumulation in plasma. The disease is inher-
ited mainly with autosomal dominant nature. The frequency of 
heterozygotes is 1: 500 in the general population (in some 
populations it is reported 1: 200 and even lower) and in homo-
zygotes 1: 1,000,000 (in some populations it is reported 1: 600 
000).
9 
The true prevalence of FH in Greece is unknown, but it is esti-
mated that there are at least 40,000 FH patients nationwide 
pointing to a prevalence of 1:250. The overwhelming majority 
of 90% remain undiagnosed.
10
  
Therefore, prompt detection of these patients is of pivotal im-
portance in order to implement appropriate preventive 
measures at a young age. National registries of FH patients 
have been a success in other countries such as Netherlands 
and Spain, as they are proved to be a significant tool for pro-
moting best clinical practices. As Greece did not have a nation-
al FH registry, the Hellenic College of Treatment of Atheroscle-
rosis (HCTA) create the National Familial Hypercholesterolemia 
Registry (GRegistry-FH, ClinicalTrials.gov Identifier: 
NCT03140605.
11,12 
Thus, the purpose of t the present article is to provide data 
related to the prevalence of FH in the Attica region.  
 
MATERIAL AND METHODS 
GRregistry-FH, Rationale 
The HCTA (a non-profit scientific organization) has established 
the national registry GRregistry-FH with ClinicalTrials.gov Iden-
tifier: NCT03140605. The primary purpose of the GRregistry-FH 
is to collate data to facilitate clinical service planning and to 




An epidemiological study was conducted between November 
2016 and December 2019. 
Participants 
One thousand five hundred seventy-eight (1578) inhabitants of 
Attica region, Greece, were included in the study. The Attica 
region was divided into 8 regional units, according to the size 
of population which was based on the latest Hellenic General 
Population Census, Hellenic Statistical Authority, ELSTAT year 
2011. An appropriate number of interviewers were determined. 
The inclusion criteria of the participants were age >18 years old 
and the ability to sign an informed consent. The exclusion cri-
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terion was the denial of an informed consent.  
Questionnaire 
A predesigned questionnaire was used to collect demographic 
and anthropometric characteristics, such as age, gender, 
height, body weight, body mass index [BMI- was calculated as 
weight (kg) / height2 (cm)]. Moreover, medical information was 
recorded such as history and management of hypertension; 
participants who had blood pressure levels ≥140/90 mmHg or 
used antihypertensive drugs were classified as hypertensive, 
according to the latest guidelines. Additionally, history of dia-
betes mellitus was recorded (fasting blood glucose> 126 mg / 
dL or/and usage of antidiabetic drugs or insulin). History of 
hypercholesterolemia was also included in the questionnaire; it 
was defined as (fasting) blood lipids levels over 200 mg/dL and 
by patient’s use of lipid-lowering agents. It was also recorded 
family medical history of CVD or related comorbidities (i.e thy-
roid disease).  
Smoking status was assessed; current smokers were defined as 
those who smoked at least on cigarette per day, former smok-
ers as those who quit smoking for more than one year.  The 
number of cigarettes per day and smoking years was also rec-
orded. As for the participants’ dietary habits, fish consumption 
per week was also taken into consideration. Alcohol consump-
tion was defined as a glass of wine (100ml) (1-2 glasses / day). 
Small consumption <3 glasses of wine / day, moderate con-
sumption 3-6 glasses of wine / day, heavy consumption > 7 
glasses / day. 
Physical activity was assessed by recording the frequency (how 
many times/week) and duration (≥20 minutes/per time). 
Criteria for FH diagnosis 
Simon Broome Register criteria for FH diagnosis were used 
according to high cholesterol levels, manifestation of prema-
ture Atherosclerotic Cardiovascular Disease (ASCVD), and pres-





All individuals enrolled on a volunteer basis so as the study 
purpose, design and workflow were explained to each partici-
pant. A written informed consent was obtained from each par-
ticipant and before the interviewer filled in the questionnaire. A 
door-to-door research method was applied. Ethical approval 




Continuous variables are presented as mean values ± standard 
deviation and categorical variables as frequencies.   X
2
 inde-
pendence test or Fisher's exact test -where necessary- were 
used to identify possible quality factors associated with the 
occurrence of familial hypercholesterolemia. Also, Student's t-
test as well as non-parametric Mann-Whitney test was used to 
test for a correlation between a quantitative risk factor and the 
incidence of the disease. The level of statistical significance was 
set at a = 5%. Data analysis was performed using SPSS ver. 20 
(SPSS Inc, Chicago, Il, USA). 
 
RESULTS 
The present study involved 1849 Greek inhabitants of Attica 
region, excluding 271 participants, as there was no information 
on the Simon Broome criteria used to diagnose FH.  Therefore, 
the studied sample consisted of 1578 Greek inhabitants of Atti-
ca region. The demographic, anthropometric and lifestyle char-
acteristics of the studied sample are presented in Table 1. The 
majority of the sample was women (59.9%). The mean age of 
the studied participants was 47.1 (±14,9) years. In Table 2, the 
results of the data analysis according to clinical characteristics 
of the studied sample are presented. According to Simon 
Broome criteria, the probability of an FH diagnosis as unlikely is 
determined in 98.7% of the studied sample, probable in 0.8% 
of the participants or definite in 0.5% of the participants, based 
on this data, the prevalence of FH in Attica region, Greece is 
1:200. Family history of the studied sample is presented in Ta-
ble 3. 
In Tables 4, 5 and 6, factors associated with FH are presented. 
Qualitative factors found to be associated with disease onset 
were medication (p-value = 0.001) and hypolipidemic therapy 
(p-value = 0.001) (Table 4). In more detail, we note the follow-
ing:  
People who take medication have a higher rate of FH com-
pared to people who do not take any medication (1.4% vs 
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0.0%). People taking hypolipidemic therapy have a higher rate 
of FH compared with people who do not receive this treatment 
(6.3% vs 0.0%) (Table 5). 
The quantitative factors found to be associated with disease 
onset were body mass index (p-value = 0.044), and systolic (p-
value = 0.001) and diastolic (p-value = 0.007) blood pressure 
(Table 6). Specifically, we observe the following: 
People with a definite diagnosis of FH have a higher body mass 
index (median 28.1 vs 25.0). In terms of systolic and diastolic 
blood pressure, people with FH show higher measurements 
than people who do not have disease (median 140.0 vs 120.0 
and median 80.0 vs 70.0 respectively). 
 
DISCUSSION 
In the present study, was described the prevalence of FH in 
1578 inhabitants of Attica region in Greece. Factors found to 
be related to the onset of the disease were medication, hypoli-
pidemic therapy, body mass index (p-value = 0.044), systolic 
and diastolic blood pressure. These data are in accordance or 




 in their study, identified that overweight/obesity 
was positively associated with FH. Moreover, Thavendiranathan 
et al.,
22
 in their study found that people with higher BMI scores 
significantly correlated with high triglyceride levels. The study 
revealed no association between patients’ physical activity lev-
els and lipid profile or BMI.  
Several clinical risk factors are significantly and independently 
associated with cardiovascular risk in patients with FH; there-
fore should be targeted for modification. There are studies that 
reveal a strong relation between factors such as myocardial 
infraction, diabetes mellitus and FH but in our study these fac-
tors were not related to FH. According to Cui et al.,
23
 FH is a 
genetic cause of premature myocardial infarction. In their 
study, they found that prevalence of FH among patient with 
premature myocardial infraction appeared relatively common. 
Besseling et al.,
24
 found that prevalence of diabetes mellitus 
was significantly lower in patients with FH than in their unaf-
fected relatives.  
Although FH is one of the most common genetic disorders, it 
remains largely underdiagnosed and undertreated. Few years 
ago, the Hellenic Atherosclerosis Society has established the 
Hellenic Familial Hypercholesterolemia Registry, part of the 
Familial Hypercholesterolemia Studies Collaboration (FHSC), to 
evaluate the characteristics and management of patients with 
FH in Greece. The conclusion derived from this study was that 
FH in Greece is characterized by a significant delay in diagnosis 




A recent study of Dumitrescu et al.,
26
 described the prevalence 
of FH in Romania by applying the Dutch Lipid Clinic Network 
(DLCN) criteria. The sample studied consisted of 59 patients, 
out of whom 61% were females. According to their results, 
91.52% of the patients had a possible FH, while 6.7% had a 
probable FH and 1.6% a definite FH diagnosis; thus, the preva-
lence of FH in Romania is: 1:213. 
Another study conducted by Benn et al.,
27
 in Copenhagen, 
found that the prevalence of FH in 98,098 participants,  was 
1:217 in the general population.
 
The prevalence of FH used to be reported as 1 in 500. Europe-
an reports suggest a higher prevalence; the US 
FH prevalence is unknown. A study reported by de Ferranti et 
al.,
28
 refers to differences by age, gender, race or ethnicity so as 
obesity status. Their results in relation to obesity status came in 
accordance to our results; more obese participants qualified as 
definite FH than non-obese. The researchers underline that 
variations in prevalence by age and obesity status suggest that 
clinical criteria may not be sufficient to estimate FH prevalence. 
Limitations 
The main limitation of the present study was participants’ abil-




In conclusion, FH is a common and treatable disorder; early 
diagnosis and treatment will improve clinical cardiovascular 
outcomes. As the vast majority of FH patients may confront 
serious problems with compliance to medical treatment or 
lifestyle modification, strategies to improve awareness and 
management of FH are definitely needed. Based on this data, 
the prevalence of FH in Attica region, Greece is 1:200. 
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ANNEX 
Table 1 . Demographic, anthropometric and lifestyle characteristics of the studied sample. 
 Ν=1578 Ν (%) 
Gender  
 Men 632 (40.1%) 
Women 946 (59.9%) 
Women >55 years old   
No 735 (77.9%) 
Yes 208 (22.1%) 
Men >45 years old   
No 290 (46.1%) 
Yes 339 (53,9%) 
Alcohol consumption  
No 427 (27,2%) 
Small  3</24h 923 (58.9%) 
Moderate 3-6/24h 204 (13.0%) 
Heavy > 7/24h 13 (0.8%) 
Exercise (> 20 minutes) / week  
At all 208 (13.3%) 
1 time 476 (30.5%) 
2 times 326 (20.9%) 
3 times 249 (15.9%) 
4 times 304 (19.4%) 
Fish consumption / week  
At all 113 (7.2%) 
1 time 848 (54.0%) 
2 times 408 (26.0%) 
3 times 121 (7.7%) 
4 times 79 (5.0%) 
Smoking  
No 986 (63.0%) 
Cessation >1 year 96 (6.1%) 
Yes 484 (30.9%) 
Electronic cigarette  
No 1519 (97.5%) 
Yes 39 (2.5%) 
Obesity status  
Underweight 31 (2.0%) 
Normal weight 750 (48.0%) 
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Overweight 516 (33.0%) 
Obese (mild) 192 (12.3%) 
Obese (moderate) 54 (3.5%) 
Obese (severe) 20 (1.3%) 
 Mean (S.D.) 




Height (cm) 169.0 (162.0-175.0) 
Weight (Kg) 72.0 (62.0-84.0) 
BMI (kg/m
2
) 25.0 (22.8-28.1) 
Systolic blood pressure (mmHg) 120.0 (110.0-130.0) 
Diastolic blood pressure (mmHg) 70.0 (70.0-80.0) 
Cigarette packet 1.0 (0.5-1.0) 
Years of smoking 20.0 (15-30) 
S.D.: Standard Deviation  
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Table 2. Clinical characteristics of the studied sample 
  Ν (%) 
Drugs  
No 1001 (63.9%) 
Yes 565 (36.1%) 
Xanthomas  
No 1527 (97.0%) 
Yes 48 (3.0%) 
Arcus Cornile  
No 1553 (98.7%) 
Yes 20 (1.3%) 
Tentom xanthomas  
No 1559 (99.2%) 
Yes 13 (0.8%) 
Xanthoma detection  
Achilleus 2 (15.4%) 
Hands 5 (38.5%) 
Knee 6 (46.2%) 
Blood pressure  
No 1312 (83.2%) 
Yes (>140/90 or drugs) 265 (16.8%) 
Diabetes mellitus  
No 1481 (94.0%) 
Yes (>126mg/dL or drugs) 95 (6.0%) 
Lipid-lowering agents  
No 1441 (91.4%) 
Yes 135 (8.6%) 
Coronary artery disease  
No 1531 (97.3%) 
Yes 42 (2.7%) 
Myocardial infarction  
No 1537 (97.7%) 
Yes 36 (2.3%) 
Stroke  
No 1512 (96.1%) 
Yes 61 (3.9%) 
Hypothyroidism  
No 1297 (85.8%) 
Yes 215 (14.2%) 
Hyperthyroidism  
No 1481 (97.9%) 
Yes 32 (2.1%) 
Classification for FH (according Simon Broome criteria) 
No disease 1557 (98,7%) 
Probable diagnosis 13 (0,8%) 
Definite diagnosis 8 (0,5%) 
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Table 3. Family history of the studied sample. 
  Ν (%) 
Relatives with high cholesterol  
No 511 (34.0%) 
Yes 992 (66.0%) 
1 612 (61.7%) 
2 262 (26.4%) 
3 66 (6.7%) 
4 52 (5.2%) 
Family history of coronary artery disease 
No 1071 (68.0%) 
Yes 503 (32.0%) 
Family history of stroke  
No 1136 (72.2%) 
Yes 437 (27.8%) 
Relatives > 90 years old  
No 1036 (65.9%) 
Yes 535 (34.1%) 
1 343 (64.6%) 
2 122 (23.0%) 
3 48 (9.0%) 
4 18 (3.4%) 
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Table 4. Qualitative factors related to prevalence of familial hypercholesterolemia and participants' habits so as the clinical characteris-
tics of the participants related to the occurrence of familial hypercholesterolemia 
 
  Familial hypercholesterolemia   
 No disease Condident Diagnosis  
  Ν(%) Ν(%) p-value 
Gender   0.066 
 Men 621(99.0%) 6(1.0%)  
Women 937(99.8%) 2(0.2%)  
Women >55 years old    0.999 
No 730(99.7%) 2(0.3%)  
Yes 204(100.0%) 0(0.0%)  
Gender   0.692 
 Men 286(99.3%) 2(0.7%)  
Women 332(98.8%) 4(1.2%)  
Alcohol consumption   0.400 
No 420(99.8%) 1(0.2%)  
Small  3</24h 915(99.6%) 4(0.4%)  
Moderate 3-6/24h 213(99.1%) 2(0.9%)  
Exercise (> 20 minutes) / week   0.999 
At all 202(99.5%) 1(0.5%)  
1-2 times 794(99.5%) 4(0.5%)  
3-4 times 547(99.5%) 3(0.5%)  
Fish consumption / week   0.272 
At all 110(99.1%) 1(0.9%)  
1 time 834(99.3%) 6(0.7%)  
2 times 407(100.0%) 0(0.0%)  
3-4 times 198(99.5%) 1(0.5%)  
Obesity status   0.150 
   Underweight /  Normal weight 775(99.7%) 2(0.3%)  
   Overweight 508(99.4%) 3(0.6%)  






  degree 260(98.9%) 3(1.1%)  
Smoking   0.082 
No 978(99.8%) 2(0.2%)  
Cessation >1 year 94(98.9%) 1(1.1%)  
Yes 474(99.0%) 5(1.0%)  
Electronic cigarette   0.071 
No 1500(99.5%) 7(0.5%)  
Yes 38(97.4%) 1(2.6%)  
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Table 5. Qualitative factors related to the clinical characteristics of the participants and related to the occurrence of familial hypercho-
lesterolemia 
 
  Familial hypercholesterolemia  
 No disease Condident Diagnosis  
  Ν(%) Ν(%) p-value 
Drugs   0.001 
No 998(100.0%) 0(0.0%)  
Yes 548(98.6%) 8(1.4%)  
Blood pressure   0.132 
No 1301(99.6%) 5(0.4%)  
Yes (>140/90 or drugs) 256(98.8%) 3(1.2%)  
Diabetes mellitus   0.999 
No 1462(99.5%) 8(0.5%)  
Yes (>126mg/dL or drugs) 94(100.0%) 0(0.0%)  
Lipid-lowering agents   0.001 
No 1436(100.0%) 0(0.0%)  
Yes 120(93.8%) 8(6.3%)  
Coronary artery disease   0.192 
No 1513(99.5%) 7(0.5%)  
Yes 40(97.6%) 1(2.4%)  
Myocardial infarction   0.166 
No 1519(99.5%) 7(0.5%)  
Yes 34(97.1%) 1(2.9%)  
Stroke   0.999 
No 1494(99.5%) 8(0.5%)  
Yes 59(100.0%) 0(0.0%)  
Hypothyroidism   0.147 
No 1287(99.8%) 3(0.2%)  
Yes 209(99.1%) 2(0.9%)  
Hyperthyroidism   0.999 
No 1465(99.7%) 5(0.3%)  
Yes 32(100.0%) 0(0.0%)  
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Table 6. Quantitative factors associated with the occurrence of familial hypercholesterolemia 
  Familial hypercholesterolemia   
 No disease Possible/Condident Diagnosis  
  Ν  Mean (S.D.) Ν  Mean (S.D.) p-value 
Age (years) 1551 47,1 (15,0) 8 54,6 (12,7) 0,129 
 Ν  
Median  
(Interquartile range) Ν  
Median  
(Interquartile range)  
BMI (kg/m
2
) 1543 25.0(22.7-28.0) 8 28.1(25.6-31.2) 0.044 
Cigarete package per day 415 1.0(0.5-1.0) 5 1.0(1.0-1.5) 0.181 
Smoking years 461 20.0(14.0-30.0) 6 30.0(28.0-35.0) 0.099 
Systolic blood pressure (mmHg) 1474 120.0(110.0-130.0) 8 140.0(130.0-150.0) 0.001 
Diastolic blood pressure (mmHg) 1466 70.0(70.0-80.0) 8 80.0(80.0-90.0) 0.007 
Blood glucose 1371 90.0(84.0-100.0) 7 90.0(82.0-110.0) 0.741 
Triglycerides without medication 
treatment 
1541 120.0(86.0-149.0) 8 135.0(100.0-234.5) 0.163 
HDL without medication treatment 1555 50.0(46.0-61.0) 8 63.0(47.7-80.0) 0.179 
Triglycerides with medication 
treatment 
109 115.0(85.0-150.0) 8 100.5(68.5-135.5) 0.325 
HDL with medication treatment 113 48.0(40.0-60.0) 8 56.5(35.0-74.3) 0.552 
Thyroid stimulating hormone 823 2.2(1.4-3.0) 5 1.2(1.0-1.2) 0.135 
Relatives >90 years old 1541 0.0(0.0-1.0) 8 0.0(0.0-0.0) 0.177 
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